医学
伊克泽珠单抗
中止
银屑病
内科学
银屑病性关节炎
队列
比例危险模型
银屑病面积及严重程度指数
药品
关节炎
皮肤病科
药理学
塞库金单抗
作者
Luca Mastorino,Paolo Dapavo,Lorenza Burzi,François Rosset,Isotta Giunipero di Corteranzo,Francesco Leo,Anna Verrone,Elena Stroppiana,Michela Ortoncelli,Simone Ribero,Pietro Quaglino
摘要
Ixekizumab showed high effectiveness and safety for up to 5 years, with survival of 2/3 of treated patients. Rapid response to treatment is predictive of long-term response.
科研通智能强力驱动
Strongly Powered by AbleSci AI